1
|
Vanni G, Pellicciaro M, Materazzo M, Buonomo OC. Axillary Reverse Mapping in Breast Cancer: Would We Need it in the Era of Surgical De-Escalation? Clin Breast Cancer 2023; 23:e377-e379. [PMID: 37419746 DOI: 10.1016/j.clbc.2023.05.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2023] [Revised: 05/21/2023] [Accepted: 05/23/2023] [Indexed: 07/09/2023]
Affiliation(s)
- Gianluca Vanni
- Department of Surgical Science, Breast Unit, PTV Policlinico Tor Vergata University, Rome, Italy
| | - Marco Pellicciaro
- Department of Surgical Science, Breast Unit, PTV Policlinico Tor Vergata University, Rome, Italy; Department of Surgical Science, PhD Program in Applied Medical-Surgical Sciences, PTV Policlinico Tor Vergata University, Rome, Italy.
| | - Marco Materazzo
- Department of Surgical Science, Breast Unit, PTV Policlinico Tor Vergata University, Rome, Italy; Department of Surgical Science, PhD Program in Applied Medical-Surgical Sciences, PTV Policlinico Tor Vergata University, Rome, Italy
| | - Oreste Claudio Buonomo
- Department of Surgical Science, PhD Program in Applied Medical-Surgical Sciences, PTV Policlinico Tor Vergata University, Rome, Italy; Department of Surgical Sciences, University Nostra Signora del Buon Consiglio, Tirana, Albania
| |
Collapse
|
2
|
Li L, Yang Y, Li W, Zhao X, He J, Mei S, Guo X, Zhang X, Ran J. Latissimus dorsi myocutaneous flap repair is effective after neoadjuvant chemotherapy for locally advanced breast cancer. World J Surg Oncol 2022; 20:134. [PMID: 35477520 PMCID: PMC9044592 DOI: 10.1186/s12957-022-02598-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2021] [Accepted: 04/16/2022] [Indexed: 12/24/2022] Open
Abstract
OBJECTIVE To describe the clinical outcome and physical condition of patients with locally advanced breast cancer (LABC) who received neoadjuvant chemotherapy followed by mastectomy and latissimus dorsi myocutaneous flap repair. METHODS A retrospective review of 142 patients with locally advanced breast cancer was selected from 1156 breast cancer patients in the South and North areas of The Affiliated Calmette Hospital of Kunming Medical University between May 2008 and December 2018. RESULTS All participants (n = 142) were women aged 40-55 years (average age 47.35 ± 0.43 years) who received neoadjuvant chemotherapy followed by mastectomy and latissimus dorsi flap repair. The median follow-up period was 16 months (range 12-24 months). For stage of disease, there were 19 cases (13%) in stage IIB, 31 cases (22%) in stage IIIA, 39 cases (28%) in stage IIIB, and 53 cases (37%) in stage IIIC, which were statistically significant with the physical condition of patients (≤ 0.001). Neoadjuvant chemotherapy was administered to shrink the tumors, and an average tumor size decrease from 10.05 ± 1.59 cm × (8.07 ± 1.54) cm to 6.11 ± 1.72 cm × (3.91 ± 1.52) cm (P < 0.001) was considered statistically significant. A t test was used for the ECOG score statistics, and the results showed that the scores were statistically significant (≤ 0.001) before and after neoadjuvant chemotherapy and after surgery. CONCLUSIONS Neoadjuvant chemotherapy is an accepted treatment option for patients with locally advanced breast cancer, and the use of a latissimus dorsi musculocutaneous flap for post-mastectomy reconstruction may improve the patients' physical condition. Our results indicated that this strategy was safe and feasible.
Collapse
Affiliation(s)
- Lu Li
- Department of Breast Surgery, The Affiliated Calmette Hospital of Kunming Medical University, No. 1228, Beijing Road, Panlong District, Kunming, 650224, Yunnan, China
| | - Yue Yang
- Department of Breast Surgery, The Affiliated Calmette Hospital of Kunming Medical University, No. 1228, Beijing Road, Panlong District, Kunming, 650224, Yunnan, China
| | - Wang Li
- Department of Hepatopancreatobiliary Surgery, The Affiliated Calmette Hospital of Kunming Medical University, No. 1228, Beijing Road, Panlong District, Kunming, 650224, Yunnan, China
| | - Xian Zhao
- Department of Plastic Surgery, The Affiliated Calmette Hospital of Kunming Medical University, No. 1228, Beijing Road, Panlong District, Kunming, 650224, Yunnan, China
| | - Jia He
- Department of Plastic Surgery, The Affiliated Calmette Hospital of Kunming Medical University, No. 1228, Beijing Road, Panlong District, Kunming, 650224, Yunnan, China
| | - Shuo Mei
- Department of Breast Surgery, The Affiliated Calmette Hospital of Kunming Medical University, No. 1228, Beijing Road, Panlong District, Kunming, 650224, Yunnan, China
| | - Xuejun Guo
- Department of Breast Surgery, The Affiliated Calmette Hospital of Kunming Medical University, No. 1228, Beijing Road, Panlong District, Kunming, 650224, Yunnan, China
| | - Xibin Zhang
- Department of Hepatopancreatobiliary Surgery, The Affiliated Calmette Hospital of Kunming Medical University, No. 1228, Beijing Road, Panlong District, Kunming, 650224, Yunnan, China
| | - Jianghua Ran
- Department of Hepatopancreatobiliary Surgery, The Affiliated Calmette Hospital of Kunming Medical University, No. 1228, Beijing Road, Panlong District, Kunming, 650224, Yunnan, China.
| |
Collapse
|
3
|
Wen G, Xin N. Dexmetomidine promotes the activity of breast cancer cells through miR-199a/HIF-1α axis. Transl Cancer Res 2021; 10:4817-4828. [PMID: 35116334 PMCID: PMC8797324 DOI: 10.21037/tcr-21-1937] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2021] [Accepted: 10/02/2021] [Indexed: 11/23/2022]
Abstract
BACKGROUND Breast cancer, as one of the most common malignant tumors in women, is still a great threat to women all over the world. Dexmetomidine (DMED) is a highly selective α2-adrenergic receptor agonist, which has attracted much attention in recent years. This study aimed to clarify the potential mechanism of DMED in regulating the activity of breast cancer cells. METHODS Breast cancer cell lines MCF-7 and MDA-MB-231 were treated with DMED. The levels of miR-199a and HIF-1α mRNA were detected using quantitative real-time polymerase chain reaction (QRT-PCR); the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) and transwell assays were applied to monitor the activity of breast cancer cells; the apoptosis of breast cancer cells was detected using the caspase-3 activity assay and flow cytometry; binding of miR-199a and HIF-1α was assessed using double luciferase reporter gene assay, and western blot was employed to monitor the level of HIF-1α in cells. RESULTS The cytotoxicity and apoptosis of MCF-7 and MDA-MB-231 cells was inhibited by DMED. It also downregulated the expression of miR-199a in breast cancer cells and enhanced the downregulation of miR-199a to promote the activity of breast cancer cells and inhibit apoptosis. Also, miR-199a targeted HIF-1α. Further functional experiments confirmed that DMED promoted the progression of breast cancer through the miR-199a/HIF-1α axis. CONCLUSIONS DMED promotes the activity of breast cancer cells through miR-199a/HIF-1αaxis. This can provide some reference for DMED in the clinical treatment of breast cancer.
Collapse
Affiliation(s)
- Gang Wen
- Department of Anesthesiology, Maternal and Child Health Hospital of Hubei Province, Wuhan, China
| | - Naixing Xin
- Department of Anesthesiology, Maternal and Child Health Hospital of Hubei Province, Wuhan, China
| |
Collapse
|